WallStreetZenWallStreetZen

NASDAQ: IMRX
Immuneering Corp Stock Forecast, Predictions & Price Target

Analyst price target for IMRX

Based on 1 analyst offering 12 month price targets for Immuneering Corp.
Min Forecast
$20.00+225.2%
Avg Forecast
$20.00+225.2%
Max Forecast
$20.00+225.2%

Should I buy or sell IMRX stock?

Based on 1 analyst offering ratings for Immuneering Corp.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IMRX stock forecasts and price targets.

IMRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-04

1 of 1

Forecast return on equity

Is IMRX forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.53%

Forecast return on assets

Is IMRX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

IMRX revenue forecast

What is IMRX's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$17.6M
Avg 2 year Forecast
$199.9M

IMRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMRX$6.15$20.00+225.20%Buy
SGMO$1.02$2.00+96.08%Hold
NVCT$10.30$21.00+103.88%Buy
GBIO$2.76$9.00+226.09%Buy
GNFT$3.67$11.00+199.73%Buy

Immuneering Stock Forecast FAQ

Is Immuneering Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: IMRX) stock is to Buy IMRX stock.

Out of 1 analyst, 0 (0%) are recommending IMRX as a Strong Buy, 1 (100%) are recommending IMRX as a Buy, 0 (0%) are recommending IMRX as a Hold, 0 (0%) are recommending IMRX as a Sell, and 0 (0%) are recommending IMRX as a Strong Sell.

If you're new to stock investing, here's how to buy Immuneering stock.

What is IMRX's revenue growth forecast for 2028-2029?

(NASDAQ: IMRX) Immuneering's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.

Immuneering's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast IMRX's revenue for 2028 to be $514,214,256, with the lowest IMRX revenue forecast at $514,214,256, and the highest IMRX revenue forecast at $514,214,256.

In 2029, IMRX is forecast to generate $5,853,726,073 in revenue, with the lowest revenue forecast at $5,853,726,073 and the highest revenue forecast at $5,853,726,073.

What is IMRX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: IMRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is IMRX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year IMRX price target, the average IMRX price target is $20.00, with the highest IMRX stock price forecast at $20.00 and the lowest IMRX stock price forecast at $20.00.

The Wall Street analyst predicted that Immuneering's share price could reach $20.00 by Mar 4, 2025. The average Immuneering stock price prediction forecasts a potential upside of 225.2% from the current IMRX share price of $6.15.

What is IMRX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: IMRX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.